Skip to content
Italfarmaco Logo

Italfarmaco: Topline Data from Phase 2 Trial with Givinostat

July 2, 2021

Italfarmaco has announced results for their Givinostat trial in Becker muscle dystrophy (BMD). Although the change in total fibrosis in muscle biopsy did not show a significant difference in 51 adult males with BMD, it did show a significant difference from placebo on muscle MRI confirming the ability of Givinostat to counteract muscle deterioration. Italfarmaco plans to speak with regulators to continue this program development.

Read the full press release here.